IRAK4 and leukemia: IRAK4 inhibitors have also entered human trials, with Emavusertib, a selective IRAK4 inhibitor, currently being evaluated in the Phase 1/2 TakeAim Leukemia trial (NCT04278768), which has shown promising preliminary efficacy [35].